Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

The impact of low-frequency and rare variants on lipid levels.

Surakka I, Horikoshi M, Mägi R, Sarin AP, Mahajan A, Lagou V, Marullo L, Ferreira T, Miraglio B, Timonen S, Kettunen J, Pirinen M, Karjalainen J, Thorleifsson G, Hägg S, Hottenga JJ, Isaacs A, Ladenvall C, Beekman M, Esko T, Ried JS, Nelson CP, Willenborg C, Gustafsson S, Westra HJ, Blades M, de Craen AJ, de Geus EJ, Deelen J, Grallert H, Hamsten A, Havulinna AS, Hengstenberg C, Houwing-Duistermaat JJ, Hyppönen E, Karssen LC, Lehtimäki T, Lyssenko V, Magnusson PK, Mihailov E, Müller-Nurasyid M, Mpindi JP, Pedersen NL, Penninx BW, Perola M, Pers TH, Peters A, Rung J, Smit JH, Steinthorsdottir V, Tobin MD, Tsernikova N, van Leeuwen EM, Viikari JS, Willems SM, Willemsen G, Schunkert H, Erdmann J, Samani NJ, Kaprio J, Lind L, Gieger C, Metspalu A, Slagboom PE, Groop L, van Duijn CM, Eriksson JG, Jula A, Salomaa V, Boomsma DI, Power C, Raitakari OT, Ingelsson E, Järvelin MR, Thorsteinsdottir U, Franke L, Ikonen E, Kallioniemi O, Pietiäinen V, Lindgren CM, Stefansson K, Palotie A, McCarthy MI, Morris AP, Prokopenko I, Ripatti S; ENGAGE Consortium.

Nat Genet. 2015 May 11. doi: 10.1038/ng.3300. [Epub ahead of print]

PMID:
25961943
2.

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Pietarinen PO, Pemovska T, Kontro M, Yadav B, Mpindi JP, Andersson EI, Majumder MM, Kuusanmäki H, Koskenvesa P, Kallioniemi O, Wennerberg K, Heckman CA, Mustjoki S, Porkka K.

Blood Cancer J. 2015 May 1;5:e309. doi: 10.1038/bcj.2015.30.

3.

Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.

Saeed K, Östling P, Björkman M, Mirtti T, Alanen K, Vesterinen T, Sankila A, Lundin J, Lundin M, Rannikko A, Nordling S, Mpindi JP, Kohonen P, Iljin K, Kallioniemi O, Rantala JK.

Int J Cancer. 2015 Jun 1;136(11):2535-45. doi: 10.1002/ijc.29303. Epub 2014 Nov 20.

PMID:
25359680
4.

A community effort to assess and improve drug sensitivity prediction algorithms.

Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G.

Nat Biotechnol. 2014 Dec;32(12):1202-12. doi: 10.1038/nbt.2877. Epub 2014 Jun 1.

PMID:
24880487
5.

A novel transcript, VNN1-AB, as a biomarker for colorectal cancer.

Løvf M, Nome T, Bruun J, Eknaes M, Bakken AC, Mpindi JP, Kilpinen S, Rognum TO, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI.

Int J Cancer. 2014 Nov 1;135(9):2077-84. doi: 10.1002/ijc.28855. Epub 2014 Mar 29.

PMID:
24687856
6.

High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.

Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M.

PLoS One. 2013 Oct 23;8(10):e77232. doi: 10.1371/journal.pone.0077232. eCollection 2013.

7.

Plasticity of blood- and lymphatic endothelial cells and marker identification.

Keuschnigg J, Karinen S, Auvinen K, Irjala H, Mpindi JP, Kallioniemi O, Hautaniemi S, Jalkanen S, Salmi M.

PLoS One. 2013 Sep 10;8(9):e74293. doi: 10.1371/journal.pone.0074293. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/cfda269a-cb46-4735-b87f-42afccb6aeb1.

8.

ARLTS1 and prostate cancer risk--analysis of expression and regulation.

Siltanen S, Fischer D, Rantapero T, Laitinen V, Mpindi JP, Kallioniemi O, Wahlfors T, Schleutker J.

PLoS One. 2013 Aug 5;8(8):e72040. doi: 10.1371/journal.pone.0072040. Print 2013.

9.

High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.

Lehtinen L, Ketola K, Mäkelä R, Mpindi JP, Viitala M, Kallioniemi O, Iljin K.

Oncotarget. 2013 Jan;4(1):48-63.

10.

Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma.

Nordberg J, Mpindi JP, Iljin K, Pulliainen AT, Kallajoki M, Kallioniemi O, Elenius K, Elenius V.

PLoS One. 2012;7(12):e50819. doi: 10.1371/journal.pone.0050819. Epub 2012 Dec 5.

11.

Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ.

Jin S, Mutvei AP, Chivukula IV, Andersson ER, Ramsköld D, Sandberg R, Lee KL, Kronqvist P, Mamaeva V, Ostling P, Mpindi JP, Kallioniemi O, Screpanti I, Poellinger L, Sahlgren C, Lendahl U.

Oncogene. 2013 Oct 10;32(41):4892-902. doi: 10.1038/onc.2012.517. Epub 2012 Nov 26.

12.

High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.

Vainio P, Mpindi JP, Kohonen P, Fey V, Mirtti T, Alanen KA, Perälä M, Kallioniemi O, Iljin K.

PLoS One. 2012;7(6):e39801. doi: 10.1371/journal.pone.0039801. Epub 2012 Jun 28.

13.

Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs.

Khan SA, Faisal A, Mpindi JP, Parkkinen JA, Kalliokoski T, Poso A, Kallioniemi OP, Wennerberg K, Kaski S.

BMC Bioinformatics. 2012 May 30;13:112. doi: 10.1186/1471-2105-13-112.

14.

A functional genetic screen reveals new regulators of β1-integrin activity.

Pellinen T, Rantala JK, Arjonen A, Mpindi JP, Kallioniemi O, Ivaska J.

J Cell Sci. 2012 Feb 1;125(Pt 3):649-61. doi: 10.1242/jcs.090704.

15.

CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.

Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J.

Oncogene. 2012 Sep 27;31(39):4266-78. doi: 10.1038/onc.2011.599. Epub 2012 Jan 16.

PMID:
22249265
16.

Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.

Björkman M, Östling P, Härmä V, Virtanen J, Mpindi JP, Rantala J, Mirtti T, Vesterinen T, Lundin M, Sankila A, Rannikko A, Kaivanto E, Kohonen P, Kallioniemi O, Nees M.

Oncogene. 2012 Jul 19;31(29):3444-56. doi: 10.1038/onc.2011.512. Epub 2011 Nov 28.

PMID:
22120715
17.

Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP, Latonen L, Vessella RL, Tammela TL, Kallioniemi O, Visakorpi T, Schleutker J.

PLoS One. 2011;6(10):e26595. doi: 10.1371/journal.pone.0026595. Epub 2011 Oct 20.

18.

Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer.

Vainio P, Wolf M, Edgren H, He T, Kohonen P, Mpindi JP, Smit F, Verhaegh G, Schalken J, Perälä M, Iljin K, Kallioniemi O.

Prostate. 2012 May 15;72(7):789-802. doi: 10.1002/pros.21487. Epub 2011 Sep 14.

PMID:
21919029
19.

HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation.

Haapa-Paananen S, Kiviluoto S, Waltari M, Puputti M, Mpindi JP, Kohonen P, Tynninen O, Haapasalo H, Joensuu H, Perälä M, Kallioniemi O.

Oncogene. 2012 Mar 8;31(10):1299-310. doi: 10.1038/onc.2011.316. Epub 2011 Jul 25.

PMID:
21785461
20.

A cell spot microarray method for production of high density siRNA transfection microarrays.

Rantala JK, Mäkelä R, Aaltola AR, Laasola P, Mpindi JP, Nees M, Saviranta P, Kallioniemi O.

BMC Genomics. 2011 Mar 28;12:162. doi: 10.1186/1471-2164-12-162.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk